Pallidal DBS improves myoclonus in 2 patients with post-hypoxic myoclonus
Objective: Describe DBS for 2 patients with severe post-hypoxic myoclonus. Background: Limited prior reports have shown improvement of PHM after DBS. We describe 2 recent…Hypnosis as an adjunctive treatment for FND, a case series
Objective: To review three cases of Functional Neurologic Disorder (FND) that resolved successfully with Hypnosis and to identify the specific techniques and reasons behind their…Understanding Social Isolation before, during and after the Covid-19 pandemic among Patients with Parkinson’s disease
Objective: The aim of this study was to understand and measure the effect of social network support in patients with Parkinson’s disease(PwP) before, during and…Establishing a Natural History of X-linked Dystonia Parkinsonism
Objective: Our main objective is to establish a comprehensive, quantitative assessment of movement dysfunction and bulbar motor impairments that are sensitive and specific to disease…The Value of Physician Assistant/Associates (PAs) in a Movement Disorder Clinic
Objective: To assess the value and productivity of physician assistants/associates (PA) in a movement disorder clinic. Background: Due to the aging population and shortage of…Validation and replication of Parkinson disease behavioral subtypes
Objective: To validate and replicate clinical subtypes of Parkinson disease. Background: We recently identified three distinct clinical subtypes of Parkinson disease: motor (predominant motor with…Effort-based decision-making and neuropsychiatric symptoms before and after subthalamic nucleus deep brain stimulation in Parkinson’s disease
Objective: Parkinson’s disease patients with apathy and patients in the medication OFF state show reduced reward sensitivity in effort-based decision-making tasks. The effect of subthalamic…The neuroprotective properties of NLX-112 in MPTP treated mice are mediated by reactive gliosis and astrocytic GDNF
Objective: To investigate whether NLX-112, a potent and selective 5-HT1A agonist is neuroprotective in a mouse MPTP model of Parkinson’s Disease (PD) [1]. Background: There…Multiple N-of-1 trials to investigate hypoxia-based treatment in Parkinson’s disease: safety and short-term effects
Objective: In this study, we describe the safety and short-term effects of the first hypoxia-based treatment trial in Parkinson’s disease by deploying a personalized multiple…Combination COMT inhibitor with Levodopa reduces consumption of vitamin B6
Objective: To investigate changes in Levodopa (LD) pharmacokinetics and changes in homocysteine, vitamin B6, and vitamin B12 in Parkinson's disease (PD) patients receiving LD formulations…
- « Previous Page
- 1
- …
- 51
- 52
- 53
- 54
- 55
- …
- 186
- Next Page »